Neither Ozempic nor Wegovy are listed on the PBS to treat obesity. When Wegovy becomes available, users will need to pay the full price. Or should the government subsidise it?
L’expertise universitaire, l’exigence journalistique
Articles sur Ozempic series
Ensemble des articles
The animal studies are promising but early research in humans show mixed results. Here’s what we know so far.
Some women who use drugs like Ozempic have reported unexpected pregnancies. What’s going on?
Does weight come back when you stop taking drugs like Ozempic? Are these medications simply another (expensive) form of yo-yo dieting? Here’s what we know so far.
We don’t tell people taking statins to treat high cholesterol or drugs to manage high blood pressure they’re cheating or taking the easy way out. Nor should we when people take drugs like Ozempic.
Many have declared drugs like Ozempic could ‘end obesity’. This isn’t just untrue – it also perpetuates fat stigma.
In Australia, Ozempic is only approved to treat diabetes but doctors are prescribing it ‘off label’ for weight loss. Compounding pharmacies have also been making their own versions to meet demand.
Ozempic generated A$21 billion of sales in 2023 alone. So how was it developed? And how are its new competitors, Mounjaro and Zepbound, different?
Early on we heard a lot about the potential benefits of drugs like Ozempic. Now we’re hearing more about the risks. But what does the latest evidence say?
Les contributeurs les plus fréquents
-
Adjunct Senior Lecturer, Nutrition, Dietetics & Food Innovation - School of Health Sciences, UNSW Sydney
-
Laureate Professor in Nutrition and Dietetics, University of Newcastle
-
Professor and Director Academic Excellence, Macquarie University
-
Lecturer Pharmacy Practice, University of Sydney
-
Associate Lecturer, Sydney Pharmacy School, University of Sydney
-
General Practitioner, PhD Candidate, Bond University
-
Karin Hammarberg est un·e ami·e de La Conversation
Senior Research Fellow, Global and Women's Health, School of Public Health & Preventive Medicine, Monash University
-
Emeritus Professor of Reproductive and Periconceptual Medicine, The Robinson Research Institute, University of Adelaide
-
Addiction Psychiatrist, Associate Professor, Monash University
-
The University of Melbourne
-
Florey Institute of Neuroscience and Mental Health
-
Head of the Obesity and Metabolic Medicine Group in the Department of Surgery, School of Translational Medicine, Monash University
-
ARC Future Fellow, School of Biomedical Sciences, The University of Queensland
-
Professor of Health Economics, Flinders University
-
Professor of Community Health and Wellbeing, The University of Queensland
